Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo tratamiento para la enfermedad de hígado graso no alcohólico

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20150424002
Publicado:
26/10/2015
Caducidad:
25/10/2016
Resumen:
Tres organismos españoles de investigación han desarrollado un método para el tratamiento de la enfermedad de hígado graso no alcohólico, en particular la esteatohepatitis. Este método se basa en el uso de una familia de amidas de ácido graso con fenilalquilaminas, que inducen una reducción del daño hepático. Además pueden emplearse para el control de la obesidad mediante un complemento alimenticio. El método tiene un perfil farmacológico seguro, presenta baja toxicidad, no causa cardiotoxicidad y pocas interacciones con enzimas metabolizantes. Se buscan socios de la industria farmacéutica para desarrollar y comercializar la tecnología mediante acuerdos de licencia.

Details

Tittle:
New treatment of non-alcoholic fatty liver disease
Summary:
Three Spanish research organisations have developed a method for treatment of non-alcoholic fatty liver diseases, in particular steatohepatitis, based on the use of a family of fatty acid amides with phenylalkylamines, which induce a reduction of liver damage. In addition, they can be used to control of obesity by means of a nutritional supplement. Partners from the pharmaceutical industry are sought to develop and commercialize the technology via licensing agreement.
Description:
Non-alcoholic fatty liver disease (NAFLD) is the most rapidly increasing cause of liver disease in the western world. A more advanced stadium of NAFLD is non-alcoholic steatohepatitis (NASH) that can lead to cirrhosis and hepatocellular cancer. NAFLD/NASH are associated to obesity, insulin resistance and metabolic syndrome, although not all patients suffer from one of these conditions.
The use of this new family of compounds induces a decrease in liver damage markers, such as transaminases (ALS and ALT) and triglyceride levels and a reduction of liver fat in obese Zucker rats models. In addition, the hepatoprotective effect is associated with a down-regulation of genes involved in the lipogenic pathway in the liver of obese rats.
Because of the common nutritional origin of NASH, food products able to confer protection against this disease are of maximum interest. Thus, these compounds could be used as a pharmaceutical drug or as a nutritional supplement in foodstuff for prevention and treatment of NASH.
This method could be also used to treat alcoholic steatohepatitis (ASH).
Advantages and Innovations:
· These compounds ameliorate the obesity-associated fatty liver by inducing hepatic lipid clearance.
· Safe pharmacological profile, low toxicity, no cardiotoxicity and little interactions with metabolizing enzymes (no drug-drug interaction expected).
· Useful also as preventive treatment for people suffering from diabetes, obesity or alcoholism which are prone to suffer steatohepatitis.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Spanish patent application filed

Partner sought

Type and Role of Partner Sought:
Pharmaceutical or biotech componies able to develop and commercialize the technology

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos